CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 56 enrolled
Drug / intervention
Periostat +1 moredrug
Likely dose
Doxycycline 20 mg orally twice daily for at least 5 days (2 days pre-op through postoperative day 3)AI-extracted
Key inclusion· 2
  • ✓Age 18 through 80 years
  • ✓Scheduled for primary CABG surgery with CPB
Key exclusion· 9
  • ✕Females of childbearing potential
  • ✕Emergency CABG
  • ✕Previous sternotomy
  • ✕Planned simultaneous surgery (valve repair or carotid endarterectomy)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00246740
NCT00246740Phase 2Completed
CompareCT.gov

Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting: A Pilot Study

University of Alberta·interventional·Posted Oct 31, 2005·Updated Dec 15, 2017

In Brief

A Phase 2 clinical trial evaluating Periostat and Placebo Oral Tablet for Coronary Artery Bypass Grafting and 2 related conditions. Completed, enrolled 56 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting (CABG) surgery with cardiopulmonary bypass (CPB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Bypass Grafting, Cardiopulmonary Bypass, Reperfusion Injury
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 31, 2005
Enrollment StartOct 1, 2005
Primary CompletionMay 1, 2008
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.7 years ago

Interventions

Periostatdrug

In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.

Placebo Oral Tabletdrug

In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.